JUFEEL INTERNATIONAL GROUP
BioSniper Score
Based on 4 of 6 signals
Market Cap
—
Cash Runway
4.5 mo
Lead Asset
pmas no. 1 (Phase 2)
Next Catalyst
—
Tracking 1 pipeline candidate · 1 clinical trial for JUFEEL INTERNATIONAL GROUP · Updated within the last hour.
Go deeper on JUFEEL INTERNATIONAL GROUP with Spotter
Ask follow-up questions and run a full multi-agent deep dive on CNJG — live, with citations.
Score breakdownBased on 4 of 6 signals · derived from public data
4.5 months
D/E 0.56 · 0% dilution
Lead: Phase 2
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Key Financialsas of September 30, 2019
Cash
$257K
Quarterly Burn
$1.1M
Revenue
$5.0M
Free Cash Flow
-$1.1M
Total Liabilities
$18.5M
Shareholders Equity
$33.2M
Current Ratio
0.27
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| pmas no. 1 | Phase 2 |
Commercialization & Governance
Commercialization
- Status
- Clinical-stage
- Has Revenue
- No
Frequently asked questions
What is JUFEEL INTERNATIONAL GROUP's lead drug candidate?
JUFEEL INTERNATIONAL GROUP's most advanced tracked candidate is pmas no. 1 (Phase 2) for women's climacteric syndrome (MPS).
What therapeutic areas does JUFEEL INTERNATIONAL GROUP focus on?
JUFEEL INTERNATIONAL GROUP develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.
Get the full picture on JUFEEL INTERNATIONAL GROUP
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.